omni
aaps
Generic Drugs: A Bargain Or Sticker Shock?
Generic Drugs: A Bargain Or Sticker Shock?
Generic drugs, normally a bargain alternative to name-brand pharmaceuticals, are providing some sticker shock of their own. Prices of generic drugs rose more steeply than inflation for 22 percent of the top-selling generics on the market, according to ...
Generic Drugs: Revolutionary Change in the Global Pharmaceutical Industry
Generic Drugs: Revolutionary Change in the Global Pharmaceutical Industry
Over the last few years, generic drugs — low-cost copies of branded drugs — have been gaining in volume and market share. Typically priced at significant discounts (50-70 percent) to their branded counterparts, health plans and governments ...
Modernizing And Strengthening Existing Laws To Control Drug Costs
Modernizing And Strengthening Existing Laws To Control Drug Costs
In his first pre-inaugural press conference on Jan. 11, President Trump stated the pharmaceutical industry has been "disastrous" and is "getting away with murder."
Another Fatal-Disease Drug in Limbo
Another Fatal-Disease Drug in Limbo
An advisory panel for the U.S. Food and Drug Administration (FDA) voted that Sarepta Therapeutics’s eteplirsen has not been proven effective in the treatment of Duchenne muscular dystrophy (DMD), a rare and fatal disease for which there is curren...
FDA Approves Selexipag For Pulmonary Arterial Hypertension
FDA Approves Selexipag For Pulmonary Arterial Hypertension
The U.S. Food and Drug Administration (FDA) has approved selexipag to treat adults with pulmonary arterial hypertension (PAH), a chronic and progressive lung disease that causes high pressure in the arteries that connect the heart to the lungs. The dru...